These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26900475)

  • 21. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
    Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
    J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Overview of HDAC Inhibitors and their Synthetic Routes.
    Peng X; Liao G; Sun P; Yu Z; Chen J
    Curr Top Med Chem; 2019; 19(12):1005-1040. PubMed ID: 30827245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
    Frew AJ; Johnstone RW; Bolden JE
    Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs.
    Needham LA; Davidson AH; Bawden LJ; Belfield A; Bone EA; Brotherton DH; Bryant S; Charlton MH; Clark VL; Davies SJ; Donald A; Day FA; Krige D; Legris V; McDermott J; McGovern Y; Owen J; Patel SR; Pintat S; Testar RJ; Wells GM; Moffat D; Drummond AH
    J Pharmacol Exp Ther; 2011 Oct; 339(1):132-42. PubMed ID: 21778281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting histone deacetylases in neuroblastoma.
    Witt O; Deubzer HE; Lodrini M; Milde T; Oehme I
    Curr Pharm Des; 2009; 15(4):436-47. PubMed ID: 19199971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis.
    Korfei M; Skwarna S; Henneke I; MacKenzie B; Klymenko O; Saito S; Ruppert C; von der Beck D; Mahavadi P; Klepetko W; Bellusci S; Crestani B; Pullamsetti SS; Fink L; Seeger W; Krämer OH; Guenther A
    Thorax; 2015 Nov; 70(11):1022-32. PubMed ID: 26359372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strategies in developing promising histone deacetylase inhibitors.
    Zhang L; Fang H; Xu W
    Med Res Rev; 2010 Jul; 30(4):585-602. PubMed ID: 19634125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
    Cosenza M; Pozzi S
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospects: histone deacetylase inhibitors.
    Dokmanovic M; Marks PA
    J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
    Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.
    Sweet MJ; Shakespear MR; Kamal NA; Fairlie DP
    Immunol Cell Biol; 2012 Jan; 90(1):14-22. PubMed ID: 22024621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
    Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M
    Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
    Hutt DM; Roth DM; Marchal C; Bouchecareilh M
    Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
    Qin HT; Li HQ; Liu F
    Expert Opin Ther Pat; 2017 May; 27(5):621-636. PubMed ID: 28033734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
    Zhou L; He X; Gao B; Xiong S
    J Virol; 2015 Oct; 89(20):10512-23. PubMed ID: 26269170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis.
    Luque-Martin R; Van den Bossche J; Furze RC; Neele AE; van der Velden S; Gijbels MJJ; van Roomen CPPA; Bernard SG; de Jonge WJ; Rioja I; Prinjha RK; Lewis HD; Mander PK; de Winther MPJ
    Front Pharmacol; 2019; 10():1242. PubMed ID: 31736752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer.
    Chiaradonna F; Cirulli C; Palorini R; Votta G; Alberghina L
    Antioxid Redox Signal; 2015 Jul; 23(1):30-50. PubMed ID: 24483782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
    Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
    Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.